The FDA review process is anticipated to be completed ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Invivyd has continued to provide timely updates to the FDA since its initial submission ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Descartes-08 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for MG and other ... reflect those of Nasdaq, Inc. Founded in the late 1990s ...

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...

Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) rose 3% in post-market trading Thursday on news the company had received FDA ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...